<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093455</url>
  </required_header>
  <id_info>
    <org_study_id>13-007023</org_study_id>
    <nct_id>NCT02093455</nct_id>
  </id_info>
  <brief_title>Effects of Chardonnay Seed Flour on Vascular Health</brief_title>
  <official_title>Effects of Chardonnay Seed Flour on Vascular Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Whole Vine Products</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded trial (Chardonnay seed flour vs. placebo - in pill form)&#xD;
      with the purpose to test the impact of a four-month supplementation with Chardonnay Seed&#xD;
      Flour (CSF) on endothelial function. Chardonnay flour is made from wine grape skins and&#xD;
      seeds. We will examine the effect of CSF on parameters such as endothelial function (via&#xD;
      EndoPAT testing), plasma lipid levels, glucose tolerance, insulin resistance, inflammatory&#xD;
      markers, oxidative stress surrogates, endothelial progenitor cells (EPCs) as well as the&#xD;
      makeup of and impact on the gut microbiome (via stool samples).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function as measured by reactive hyperemia EndoPAT scores</measure>
    <time_frame>Baseline to 4 months</time_frame>
    <description>Endothelial function (Endothelial Peripheral Arterial Tonometry - EndoPAT) Testing will generate a score at baseline that will be compared to a second EndoPAT test which will be conducted again after the study subjects have taken the study product for 4 months. These scores will be used to determine if the study product had an effect on endothelial function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in High Sensitive C-reactive protein (hsCRP)</measure>
    <time_frame>Baseline to 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>1. Endothelial Dysfunction (EndoPAT Score &lt;=2)</condition>
  <arm_group>
    <arm_group_label>Chardonnay Seed Flour (CSF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prepackaged capsules taken 3 times per day. During the first month, the total dose will be 15 g/d. For months 2-4, the total dose will be 30 g/d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pre-packaged capsules taken 3 times per day. For the first month, a total of 15 g/d. During months 2 - 4, a total of 30 g/d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chardonnay Seed Flour (CSF)</intervention_name>
    <description>CSF is made from wine grape skins and seeds.</description>
    <arm_group_label>Chardonnay Seed Flour (CSF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;= 18 years old&#xD;
&#xD;
          2. Demonstrated endothelial dysfunction (EndoPAT score &lt;= 2) at time of screening.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Age below 18 or above 80&#xD;
&#xD;
          2. Endothelial function greater than 2.0 at baseline&#xD;
&#xD;
          3. Hypertension (at screening): any patient with systolic blood pressure (SBP &gt;=170 mmHg&#xD;
             or diastolic blood pressure &gt;= 110 mmHg, or hypotension (SBP &lt; 100 mmHg&#xD;
&#xD;
          4. Abnormal liver function tests&#xD;
&#xD;
          5. Uncontrolled Diabetes Mellitus or the use of metformin for Diabetes Mellitus&#xD;
&#xD;
          6. Difficulty swallowing capsules&#xD;
&#xD;
          7. Gastrointestinal disease manifesting with symptoms of malabsorption such as celiac&#xD;
             disease or Crohn's disease&#xD;
&#xD;
          8. Non-English speakers&#xD;
&#xD;
          9. Vulnerable populations unable to consent such as prisoners or dependents&#xD;
&#xD;
         10. Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of the CSF including, but not limited to, any&#xD;
             of the following:&#xD;
&#xD;
               1. History of major gastrointestinal tract surgery such as gastrectomy,&#xD;
                  gastroenterostomy or bowel resection&#xD;
&#xD;
               2. Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic&#xD;
                  function/injury as indicated by abnormal lipase or amylase&#xD;
&#xD;
               3. Evidence of hepatic disease as determined by a history of hepatic encephalopathy,&#xD;
                  a history of cirrhosis, esophageal varices, or a history of portocaval shunt.&#xD;
&#xD;
         11. History of hypersensitivity to any of the study supplement or suspected&#xD;
             contraindications to the study supplement.&#xD;
&#xD;
         12. History of noncompliance to medical regimens or unwillingness to comply with the study&#xD;
             protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Lerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Amir Lerman</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Endothelial function</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

